Head-to-head · free

Ascentage Pharma Group International vs AbCellera Biologics Inc.

AAPG vs ABCL — return on capital, cash generation, margins and balance sheet side by side.

AAPG

2 / 3

measures where AAPG leads

ABCL

1 / 3

measures where ABCL leads

A simple count of which company scores better on each measure — not a recommendation to buy or sell.

MeasureAAPGABCL · FY2025
Revenue—$75.1M
Net income—(146.4M)
Revenue growth (yearly, multi-year)—-33.1%
Free cash flow—(174.1M)
Free cash flow margin—-231.7%
Net cash / (debt)——
ROIC——
Return on equity-156.5%-14.5%
Gross margin91.5%—
Operating margin-208.6%-270.5%
Net debt / EBITDA0.46x0.68x

Figures are as reported by each company; latest fiscal year shown.

Where Ascentage Pharma Group International's cash went

Not reported yet.

Full AAPG profile →

Where AbCellera Biologics Inc.'s cash went (FY2025)

Capital spending
$42.8M
Buybacks
—
Dividends
—
Acquisitions
—
Net debt issued / (repaid)
—
Full ABCL profile →

Ask which business is stronger

"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.

Compare them free

More comparisons